Biocon, IATRICa to develop immunoconjugates against Cancer

Bangalore, Jan 17 (UNI) Pharma major Biocon Ltd and IATRICa Inc today announced a strategic partnership to co-develop an exclusive new class of immunoconjugates for immunotherapy of cancers and infectious diseases.

The companies would co-develop candidate products based on IATRICa's technology platform and Biocon's proven expertise in drug development, biologics manufacturing, and clinical research, a Biocon release here said.

IATRICa's technology enabled development of a diverse spectrum of immunoconjugates that were capable of activating potent targeted immune responses against various tumours or pathogens.

They would leverage and integrate their synergistic Research and Development expertise to formulate and test next-generation antibody-based immunoconjugates that were more effective than current therapeutic antibodies for cancers and infectious disorders.

In addition to a co-development and licensing agreement, Biocon had also made an equity investment in IATRICa.

UNI RM RS GD PBB BST1723